Estrella shares rise 11.05% intraday as EB103 advances to Phase II with positive safety data and 100% complete response rate.

Estrella Immunopharma surged 11.05% intraday after announcing that its EB103 therapy advanced to Phase II trials following a positive recommendation from an independent Data Safety Monitoring Board (DSMB). The DSMB confirmed a favorable safety profile with no treatment-related serious adverse events, even in high-risk patients, and noted a 100% complete response rate in the high-dose cohort of Phase I. The company emphasized EB103’s potential as a best-in-class CD19 CAR-T therapy for relapsed/refractory B-cell non-Hodgkin’s lymphoma, including high-risk subgroups ineligible for existing treatments. Multiple news reports highlighted the Phase II advancement and preliminary efficacy data, aligning with the stock’s sharp intraday rise.